Switch theme
Sign up to access all valuation multiples
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.
2014
2
Last FY Revenue n/a
LTM EBITDA -$1.7M
$28.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Elicera Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$1.7M.
In the most recent fiscal year, Elicera Therapeutics achieved revenue of n/a and an EBITDA of -$1.7M.
Elicera Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Elicera Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$1.7M | XXX | -$1.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$1.7M | XXX | -$1.7M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$1.6M | XXX | -$1.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Elicera Therapeutics's stock price is SEK 6 (or $1).
Elicera Therapeutics has current market cap of SEK 302M (or $31.1M), and EV of SEK 275M (or $28.4M).
See Elicera Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28.4M | $31.1M | XXX | XXX | XXX | XXX | $-0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Elicera Therapeutics has market cap of $31.1M and EV of $28.4M.
Elicera Therapeutics's trades at n/a EV/Revenue multiple, and -17.2x EV/EBITDA.
Equity research analysts estimate Elicera Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Elicera Therapeutics has a P/E ratio of -19.4x.
See valuation multiples for Elicera Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $31.1M | XXX | $31.1M | XXX | XXX | XXX |
| EV (current) | $28.4M | XXX | $28.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -17.2x | XXX | -17.2x | XXX | XXX | XXX |
| EV/EBIT | -17.2x | XXX | -16.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -19.4x | XXX | -18.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -11.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialElicera Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.9M for the same period.
Elicera Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Elicera Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Elicera Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -161% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Elicera Therapeutics acquired XXX companies to date.
Last acquisition by Elicera Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Elicera Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Elicera Therapeutics founded? | Elicera Therapeutics was founded in 2014. |
| Where is Elicera Therapeutics headquartered? | Elicera Therapeutics is headquartered in Sweden. |
| How many employees does Elicera Therapeutics have? | As of today, Elicera Therapeutics has 2 employees. |
| Is Elicera Therapeutics publicy listed? | Yes, Elicera Therapeutics is a public company listed on STO. |
| What is the stock symbol of Elicera Therapeutics? | Elicera Therapeutics trades under ELIC ticker. |
| When did Elicera Therapeutics go public? | Elicera Therapeutics went public in 2021. |
| Who are competitors of Elicera Therapeutics? | Similar companies to Elicera Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Elicera Therapeutics? | Elicera Therapeutics's current market cap is $31.1M |
| Is Elicera Therapeutics profitable? | Yes, Elicera Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Elicera Therapeutics? | Elicera Therapeutics's last 12 months EBITDA is -$1.7M. |
| What is the current EV/EBITDA multiple of Elicera Therapeutics? | Current EBITDA multiple of Elicera Therapeutics is -17.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
